Section 04 · the ten questions
Things people ask.
Each pair of speech bubbles is a question and the cited research answer. No recommendations. No dosing instructions. Just the literature, drawn into the margin.
What is sermorelin, and how is it different from growth hormone itself?
Sermorelin is not growth hormone. It is a 29-amino-acid synthetic peptide that corresponds to the first 29 residues of human growth hormone-releasing hormone (GHRH), the hypothalamic signal that asks the pituitary to make GH [1]. Sermorelin binds the GHRH receptor on pituitary somatotroph cells and stimulates them to release the body's own GH in pulses. Recombinant human growth hormone, by contrast, is the GH molecule itself, supplied exogenously. The functional difference is that sermorelin's effect is constrained by the body's somatostatin feedback loop, so GH and IGF-1 elevations remain within physiological range; exogenous GH bypasses that ceiling entirely [8].
How does sermorelin work at the molecular level?
Sermorelin binds the GHRH receptor, a Gs-coupled GPCR on the surface of pituitary somatotrophs. Receptor activation switches on adenylyl cyclase, raising intracellular cAMP. cAMP activates protein kinase A. PKA phosphorylates CREB, driving GH gene transcription, and simultaneously triggers exocytosis of preformed GH-containing granules — so GH rises in the bloodstream within minutes [1][10]. A 2025 review confirms this canonical cAMP/PKA/CREB pathway and documents additional MAPK/ERK and PI3K-Akt activation in peripheral tissues like cardiomyocytes [10]. Circulating GH then induces hepatic IGF-1, which mediates most of the downstream anabolic signaling [1].
What is sermorelin's half-life, and why does its effect last longer than the drug itself?
Plasma half-life in humans is approximately 11-12 minutes after subcutaneous or intravenous administration [7]. Peak plasma concentrations appear 5-20 minutes after a subcutaneous dose, and absolute bioavailability via the subcutaneous route is around 6 percent. But the stimulated GH response from the pituitary persists for roughly three hours after a single sermorelin dose [7]. The molecule's job is to flip a switch at the receptor; once flipped, the pituitary signaling cascade continues without it. Half-life of the ligand is short; half-life of the effect is longer.
Is sermorelin FDA approved? What is its current regulatory status?
Sermorelin acetate was FDA-approved in 1997 for treatment of idiopathic GH deficiency in children (marketed as Geref) and as a diagnostic GH-stimulation testing agent (Geref Diagnostic) [14]. In 2008 the manufacturer voluntarily discontinued commercial production [12]. Since then, no FDA-approved finished sermorelin product has been available on the U.S. market [12]. The molecule is currently dispensed in the U.S. only through licensed 503A and 503B compounding pharmacies on individual physician prescription. A 2024 clinical update describes how the absence of recombinant GHRH for stimulation testing has shifted U.S. diagnostic protocols toward macimorelin and glucagon-based tests [12].
What does the published research say about sermorelin's effects on IGF-1 and body composition?
In the 16-week Khorram trial of 10 mcg/kg nightly in 47 adults aged 55-71, IGF-1 rose within two weeks and stayed elevated for the full study duration. Skin thickness increased in both sexes. In men, lean body mass rose and insulin sensitivity improved on clamp testing [3]. In the 20-week Baker trial of 1 mg/day in 137 older adults, IGF-1 rose 117% (still within the physiological range), body fat fell 7.4 percent, and lean mass rose 3.7 percent [6]. The Koutkia HIV-lipodystrophy RCT using 1 mg twice daily for 12 weeks raised IGF-1 by 104 ng/mL versus 6 ng/mL on placebo, increased lean mass by 0.9 kg, and reduced trunk fat by 0.4 kg [5]. The strongest body-composition data in the GHRH-analog class comes from tesamorelin trials, not native sermorelin trials [11][13].
How does sermorelin compare to tesamorelin, CJC-1295, and ipamorelin?
Tesamorelin is GHRH(1-44) with an N-terminal trans-3-hexenoyl modification at Tyr1 that extends its half-life and resists DPP-IV cleavage. It has the strongest body-composition and hepatic-fat-reduction data in the class [11][13]. CJC-1295 is GHRH(1-29) with substitutions (notably D-Ala2) that resist DPP-IV cleavage; some versions add a drug-affinity complex (DAC) for further half-life extension. Ipamorelin is a different mechanism entirely — it is a pentapeptide ghrelin-mimetic acting at the GHS-R1a receptor, not GHRH-R. The published literature describes synergistic GH pulses when a GHRH analog is co-administered with a GHS-R1a agonist, because the two pathways converge on the somatotroph through complementary signaling [9]. None of these comparators are currently FDA-approved as finished outpatient drug products in the U.S. for the indications most often discussed.
Why is sermorelin banned by WADA?
Sermorelin and other GHRH analogs are listed in WADA Category S2 — Peptide Hormones, Growth Factors, Related Substances, and Mimetics — and are prohibited at all times in athletes covered by the WADA code [18]. The rationale tracks the mechanism: sermorelin elevates endogenous GH and IGF-1, which can confer performance advantages in tissues sensitive to GH-axis signaling. Validated LC-HRMS/MS analytical methods detect sermorelin and related GHRH analogs in athlete biological matrices, and detection windows have been characterized for anti-doping enforcement [18].
What side effects have been reported in sermorelin clinical trials?
In published trials, the most commonly reported adverse events have been local injection-site reactions (erythema, mild swelling, occasional pain at the subcutaneous injection site) and transient flushing. The 1996 pediatric Geref trial reported no significant changes in glucose, insulin, lipid, or other safety biochemistry markers across 110 children dosed nightly for at least six months [2]. The Baker 20-week trial in older adults observed adverse events in 68% on active versus 36% on placebo — primarily local skin reactions and joint pain [6]. The Khorram aging trial reported transient hyperlipidemia that resolved by study end [3]. Long-term cardiovascular, neoplasia, and mortality outcome data for chronic GHRH-analog use in adults are sparse — that is one of the most-cited gaps in the literature.
How is sermorelin reconstituted and stored in research settings?
Lyophilized sermorelin acetate is reconstituted with bacteriostatic water (sterile water containing 0.9% benzyl alcohol) for use in research. Under USP <797> compounding-pharmacy framework, reconstituted solutions stored refrigerated at 2-8 °C retain greater than 95 percent of label potency for approximately 28 days [17]. Reconstitution in plain sterile water (without preservative) results in substantially faster degradation. Handling considerations from the literature: do not shake the vial (mechanical denaturation), protect from light, and avoid repeated freeze-thaw cycles [17].
Why does sermorelin dosing in the literature concentrate on nighttime administration?
Endogenous GH secretion is sharply pulsatile, with the largest pulses occurring during slow-wave (deep) sleep. The Obal and Krueger review of GHRH and sleep regulation documents that GHRH signaling promotes slow-wave sleep amplitude and duration in both humans and animal models, and that GHRH antagonism reduces both non-REM sleep and nocturnal GH pulse amplitude [15]. The trial literature aligns exogenous GHRH-analog dosing with the body's most receptive endogenous window — late evening, subcutaneous, before sleep. The mechanism is also why several trials report incidental improvements in sleep quality alongside the GH/IGF-1 endpoints they were designed to measure [15].